Header

UZH-Logo

Maintenance Infos

Barriers to Accrual and Enrollment in Brain Tumor Trials


Lee, Eudocia Q; Chukwueke, Ugonma N; Hervey-Jumper, Shawn L; et al; Weller, Michael (2019). Barriers to Accrual and Enrollment in Brain Tumor Trials. Neuro-Oncology:Epub ahead of print.

Abstract

Many factors contribute to the poor survival of malignant brain tumor patients, some of which are not easily remedied. However, one contributor to the lack of progress that may be modifiable is poor clinical trial accrual. Surveys of brain tumor patients and neuro-oncology providers suggest that clinicians do a poor job of discussing clinical trials with patients and referring patients for clinical trials. Yet, data from the Cancer Action Network of the American Cancer Society suggest that most eligible oncology patients asked to enroll on a clinical trial will agree to do so. To this end, the Society for Neuro-Oncology (SNO) in collaboration with the Response Assessment in Neuro-Oncology (RANO) Working Group, patient advocacy groups, clinical trial cooperative groups including the Adult Brain Tumor Consortium (ABTC), and other partners are working together with the intent to double clinical trial accrual over the next five years. Here we describe the factors contributing to poor clinical trial accrual in neuro-oncology and offer possible solutions.

Abstract

Many factors contribute to the poor survival of malignant brain tumor patients, some of which are not easily remedied. However, one contributor to the lack of progress that may be modifiable is poor clinical trial accrual. Surveys of brain tumor patients and neuro-oncology providers suggest that clinicians do a poor job of discussing clinical trials with patients and referring patients for clinical trials. Yet, data from the Cancer Action Network of the American Cancer Society suggest that most eligible oncology patients asked to enroll on a clinical trial will agree to do so. To this end, the Society for Neuro-Oncology (SNO) in collaboration with the Response Assessment in Neuro-Oncology (RANO) Working Group, patient advocacy groups, clinical trial cooperative groups including the Adult Brain Tumor Consortium (ABTC), and other partners are working together with the intent to double clinical trial accrual over the next five years. Here we describe the factors contributing to poor clinical trial accrual in neuro-oncology and offer possible solutions.

Statistics

Citations

Dimensions.ai Metrics
1 citation in Web of Science®
1 citation in Scopus®
Google Scholar™

Altmetrics

Downloads

1 download since deposited on 30 Oct 2019
1 download since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:7 June 2019
Deposited On:30 Oct 2019 15:42
Last Modified:30 Oct 2019 15:46
Publisher:Oxford University Press
ISSN:1522-8517
OA Status:Closed
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1093/neuonc/noz104
PubMed ID:31175826

Download

Closed Access: Download allowed only for UZH members

Content: Accepted Version
Filetype: PDF - Registered users only until 7 June 2020
Size: 351kB
View at publisher
Embargo till: 2020-06-07